PACTR201704002194318.

Trial name or title	Assessment of botulinum toxin type A in the treatment of hand eczema
Methods	Randomised double‐blind placebo‐controlled parallel‐group study
Participants	60 patients with hand eczema Inclusion criteria Active symptomatic palmar hand eczema  Bilateral involvement 18 to 70 years of age Exclusion criteria Skin infection at the site of injection  History of use of botulinum toxin in the last 4 months Pregnancy, lactation in females Any contraindication to botulinum toxin injection including associated disorder that may affect neuromuscular function, like myasthenia gravis and Lambert‐Eaton disease History of previous allergy to BTXA
Interventions	Intervention: • Intradermal palmar injection of a minimum of 50 units of botulinum toxin type A combined with topical corticosteroids • Topical betamethasone twice daily
Outcomes	Primary outcome of the trial Visual linear analogue scale of pruritus at baseline at the third day, end of first week, fourth week, then monthly for a whole period of 6 months Secondary outcomes of the trial Hand eczema severity index at baseline at third day, end of first week, fourth week, then monthly for a whole period of 6 months
Starting date	2017‐04‐15
Contact information	Carmen Amin El Areesh Street, No. 2, Smouha, 3rd floor #302 21646 Alexandria Egypt 002‐01222966670 carmen271173@yahoo.com
Notes	Sponsor: Dermatology Department, Faculty of Medicine, University of Alexandria

BTXA: botulinum toxin A.

DLQI: Dermatology Life Quality Index.

ECG: electrocardiogram.

EQ‐5D: standardised index for measuring quality of life by the EuroQol in 5 dimensions.

HECSI: hand eczema severity index.

mTLSS: modified total lesion symptom score.

PaGA: participants' global assessment.

PBI‐HE: patient benefit index for chronic hand eczema.

PeDeSi: Person‐Centered Dermatology Self‐Care Index.

PGA: physicians' global assessment.

PUVA: (topical and oral) psoralen combined with UVA.

QALY: quality‐adjusted life‐year.

TLSS: total lesion symptom score.

UVB: ultraviolet B.